Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$766M |
| 2 |
Adobe
ADBE
|
$529M |
| 3 |
Merck
MRK
|
$463M |
| 4 |
Tesla
TSLA
|
$359M |
| 5 |
AGN
Allergan plc
AGN
|
$339M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$714M |
| 2 |
Gilead Sciences
GILD
|
$600M |
| 3 |
Perrigo
PRGO
|
$585M |
| 4 |
EMC
EMC CORPORATION
EMC
|
$448M |
| 5 |
Morgan Stanley
MS
|
$423M |
Sector Composition
| 1 | Healthcare | 17.95% |
| 2 | Consumer Discretionary | 15% |
| 3 | Communication Services | 10.58% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
526
Amgen
AMGN
$153B
| $3.22M | ﹤0.01% |
28,179
-284,144
| -91% | -$32.4M |
|
|
NAK
527
Northern Dynasty Minerals
NAK
$466M
| $3.14M | ﹤0.01% |
2,454,438
| – | – |
|
528
Southwest Airlines
LUV
$16.5B
| $3.13M | ﹤0.01% |
165,878
-71,901
| -30% | -$1.35M |
|
|
OCRX
529
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $3.09M | ﹤0.01% |
238,152
| – | – |
|
|
QLTI
530
DELISTED
QLT Inc
QLTI
| $3.05M | ﹤0.01% |
548,164
+2,052
| +0.4% | +$11.4K |
|
531
Johnson & Johnson
JNJ
$430B
| $3.03M | ﹤0.01% |
33,065
-1,906
| -5% | -$175K |
|
532
Lindsay Corp
LNN
$1.53B
| $2.98M | ﹤0.01% |
35,972
-790
| -2% | -$65.4K |
|
533
Berkshire Hathaway Class B
BRK.B
$1.08T
| $2.95M | ﹤0.01% |
24,915
-643
| -3% | -$76.2K |
|
534
Quest Diagnostics
DGX
$20.5B
| $2.95M | ﹤0.01% |
+55,037
| New | +$2.95M |
|
535
Bloomin' Brands
BLMN
$605M
| $2.94M | ﹤0.01% |
122,594
-266,117
| -68% | -$6.39M |
|
536
Piper Sandler
PIPR
$5.79B
| $2.93M | ﹤0.01% |
74,065
-28,962
| -28% | -$1.15M |
|
537
Gyre Therapeutics
GYRE
$698M
| $2.89M | ﹤0.01% |
885
+3
| +0.3% | +$9.81K |
|
|
XNPT
538
DELISTED
XENOPORT, INC.
XNPT
| $2.82M | ﹤0.01% |
490,723
-374,816
| -43% | -$2.16M |
|
|
MXT
539
DELISTED
MAXCOM TELECOMUNICACIONES S A DE C V SPONSORED ADR REP (MX)
MXT
| $2.78M | ﹤0.01% |
1,706,000
| – | – |
|
540
Watts Water Technologies
WTS
$9.35B
| $2.72M | ﹤0.01% |
43,974
-733
| -2% | -$45.4K |
|
541
BioCryst Pharmaceuticals
BCRX
$1.74B
| $2.72M | ﹤0.01% |
357,352
-92,648
| -21% | -$704K |
|
542
MacroGenics
MGNX
$126M
| $2.71M | ﹤0.01% |
+98,606
| New | +$2.71M |
|
|
STML
543
DELISTED
Stemline Therapeutics, Inc.
STML
| $2.69M | ﹤0.01% |
+137,186
| New | +$2.69M |
|
|
RGLS
544
DELISTED
Regulus Therapeutics
RGLS
| $2.66M | ﹤0.01% |
2,995
+12
| +0.4% | +$10.6K |
|
|
INFN
545
DELISTED
Infinera Corporation Common Stock
INFN
| $2.65M | ﹤0.01% |
270,583
-703,823
| -72% | -$6.88M |
|
546
Ciena
CIEN
$16.5B
| $2.52M | ﹤0.01% |
105,346
+11,271
| +12% | +$270K |
|
547
Loews
L
$20B
| $2.49M | ﹤0.01% |
+51,601
| New | +$2.49M |
|
548
Woodward
WWD
$14.6B
| $2.45M | ﹤0.01% |
53,804
-294,273
| -85% | -$13.4M |
|
|
TRAK
549
DELISTED
DEALERTRACK TECHNOLOGIES, INC. COM STK
TRAK
| $2.43M | ﹤0.01% |
50,514
-67,816
| -57% | -$3.26M |
|
550
iShares Core S&P 500 ETF
IVV
$664B
| $2.31M | ﹤0.01% |
12,416
+2,112
| +20% | +$392K |
|